Abstract: 211 words Introduction: 359 words
Introduction
Intestinal metabolism has been reported to be responsible for the low bioavailability of approximately 50% of orally-administered drugs Thummel 2007; Wacher et al. 2001; Watkins 1992) . In vitro evaluation of intestinal drug metabolism therefore represents an experimental approach that can be applied to guide the development of drugs with acceptable oral bioavailability.
The commonly used in vitro model of intestinal mucosal epithelium, the colon adenocarcinoma Caco2 cell line, while useful in defining permeability and P-gp efflux, is generally not considered appropriate for the evaluation of enteric drug metabolism due to the low basal level of drug metabolizing enzyme activity (Nakamura et al. 2002; Prueksaritanont et al. 1996) . To overcome this deficiency, Caco2 cells have been transfected with human P450 isoforms, especially CYP3A4, for the evaluation of drug bioavailability in the presence of P450 metabolism (Crespi et al. 1996; Kublbeck et al. 2016 ). However, this approach is far from representative of intestinal metabolism which is known to involve multiple pathways, including various P450 isoforms and non-P450 drug metabolizing enzymes (Nakamura et al. 2016 ; Paine et al. 2006 ). Current in vitro experimental models of human intestinal metabolism include human intestinal microsomes (Galetin et al. 2008; Kolars et al. 1992) , precision cut intestinal slices (van de Kerkhof et al. 2008) , and freshly isolated enterocytes Bonnefille et al. 2011; Hansen et al. 2000; Zhang et al. 2003) . Of these systems, primary enterocytes may represent the most physiologically relevant model, akin to primary hepatocytes for hepatic metabolism. Intact enterocytes possess key cellular properties which are key to the assessment of in vivo events including an intact plasma membrane to allow modeling of membrane permeability, uptake and efflux drug transporters, as well as complete and uninterrupted drug metabolizing enzyme pathways and cofactors for both phase I oxidation and phase II conjugation.
In our laboratory, we embarked upon the isolation and cryopreservation of enterocytes with the goal of developing a physiologically relevant experimental model for the evaluation of intestinal uptake, metabolism and efflux. We report here our success in the isolation and cryopreservation of human enterocytes to retain viability and drug metabolism enzyme activities.
This article has not been copyedited and formatted. The final version may differ from this version. Enterocyte isolation and cryopreservation. Isolation of enterocytes from human intestines was performed via enzymatic digestion of the intestinal lumen based on procedures previously reported for porcine intestines Hansen et al. 2000) . The follow lengths (post-pyloric sphincter) were used to aid the identification of the various regions of the small intestine for enterocyte isolation: duodenum: 26 centimeters (9.84 inches), jejunum: 2.5 meters (8.2 feet) and ileum: 3.5 meters. The intestines were recovered with a warm ischemic time of less than 15 minutes, and shipped to our laboratory on wet ice in University of Wisconsin Preservation Solution, with a cold ischemic time of less than 24 hours. Laboratories, Columbia, MD) that was pre-warmed in a 37°C water bath. The thawed enterocytes were recovered by centrifugation at 100 x g for 10 min at room temperature. After centrifugation, the supernatant was removed by decanting. A volume of 250 µl of 4°C Hepatocyte/Enterocyte Incubation Medium, (HQM TM , In Vitro ADMET Laboratories, Columbia, MD) was added to the intact pellet of enterocytes at the bottom of the conical tube followed by gently agitation to reconstitute an enterocyte suspension. Viability and yield were quantified in a hemacytometer based on trypan blue dye exclusion (Sigma-Aldrich).
Measurement of enterocyte diameter. Photomicrographs of the enterocytes were taken using a phase contrast photomicroscope. The photomicrographs were printed and the diameters were measured and corrected for the magnification factor. Results (µm) are expressed as mean and standard deviation values of 50 randomly chosen cells from each enterocyte lot.
This article has not been copyedited and formatted. The final version may differ from this version. Incubation of enterocytes with drug metabolizing enzyme substrates. DME substrate incubations were performed in a cell culture incubator maintained at 37°C with a humidified atmosphere of 5% CO2.
Enterocyte cell density was adjusted to 3 x 10 6 cells/ml in HQM TM . Aliquots of 50 µl cell suspension were added to individual wells (150,000 viable enterocytes/well) of a 96-well plate for the evaluation of drug metabolism activities. After cell addition, the 96-well plate was pre-warmed in the incubator for 15 min,
followed by the addition of 50 µl of pre-warmed (37°C) HQM TM containing DME substrates at 2x final concentration and incubated for 2 hrs. The final incubation mixture in each well therefore had a volume of 100 l, with a cell density of 1.5 x 10 6 cells/ml. Substrates for the multiple drug metabolism pathways evaluated are shown in Table 1 . Metabolism was terminated in each well by the addition of 100 µl acetonitrile. The final incubation samples were stored at -80°C for the subsequent LC/MS-MS analysis.
LC/MS-MS quantification of metabolite formation.
Upon thawing, an aliquot of 100 µl of acetonitrile containing an internal standard of 250 nM tolbutamide was added to each sample. All samples were centrifuged at 13,000 rpm for 5 minutes. An aliquot of 100 µL of supernatant from each was transferred to a 96 well plate and was diluted with 200 µL of deionized water for LC/MS-MS analysis using an API 4000 QTRAP mass spectrometer with an electrospray ionization source (AB SCIEX, Framingham, MA) connected to Agilent 1200 series HPLC (Agilent Technologies, Santa Clara, CA). An Agilent Zorbax Eclipse Plus C18 column (4.6 x 75 mm i.d., 3.5 μm; Agilent Technologies, Santa Clara, CA) at a flow rate of 1 mL/min was used for the chromatography separation. The mobile phase consisted of 0.1 % formic acid in acetonitrile (A) and 0.1 % formic acid in water (B). The gradient for the positive ion mode operation was programed as: 0 to 2.5 min, increase B from 5 to 95%; 2.5 to 3.5 min, 95% B; 3.5 to 3.6 min, decrease B to 5%; run-time 5 min. The gradient program for the negative ion mode was: 0 to 3 min, Table 2 .
Morphology, size, viability and yield of cryopreserved human enterocytes. The morphology of cryopreserved human enterocytes immediately after recovery is shown in Figure 1 . The enterocytes consisted of either single cells or small cell clusters, with a rounded morphology typical of mammalian cells in suspension. The average post-thaw viability of human enterocytes for the 25 donors was 84.7  4.7% with a range of 78% to 95%, with an average diameter of 14.9  1.0 m (Table 2) .
Drug metabolizing enzyme activities.
Metabolism of 14 substrates using pooled human enterocytes: Human enterocytes from 4 male and 4 female donors were combined (pooled) and incubated with 14 pathway-selective substrates for the evaluation of their drug metabolism potential. Results are shown in Table 3 .
Individual variations in drug metabolizing enzyme activities:
Enterocytes from 24 donors were evaluated for CYP2C9 (diclofenac 4-hydroxylation), CYP2C19 (s-mephenytoin 4-hydroxylation), CYP3A4
(midazolam 1'-hydroxylation and testosterone 6β-hydroxylation), CYP2J2 (astemizole O-demethylation), CES (irinotecan hydrolysis), UGT (7-hydroxycoumarin glucuronidation), and SULT (7-hydroxycoumarin sulfation) activities. Results are shown in Table 4 .
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Intestinal uptake, efflux, and metabolism are the three key determinants of bioavailability of orally administered drugs. Enterocytes isolated from the small intestines represent an ideal model to evaluate these determinants. Successful isolation of primary enterocytes to retain drug metabolizing enzyme activities have been previously reported using a variety of procedures including the following: from mice via EDTA perfusion , from pigs via collagenase digestion , and from humans via mechanical separation (Chougule et al. 2012) . Our report here represents the first to report successful cryopreservation of primary enterocytes isolates from humans to retain viability and drug metabolizing enzyme activities. Using enterocytes pooled from 4 male and 4 female donors, quantifiable metabolite formation was observed for CYP2C8 (paclitaxel 6α-
hydroxylation), CYP2C9 (diclofenac 4-hydroxylation), CYP2C19 (s-mephenytoin 4-hydroxylation), CYP2E1
(chlorzoxazone 6-hydroxylation), CYP3A4 (midazolam 1'-hydroxylation and testosterone 6β-hydroxylation), CYP2J2 (astemizole O-demethylation), CES (irinotecan hydrolysis), UGT (7-hydroxycoumarin glucuronidation), and SULT (7-hydroxycoumarin sulfation). Undetectable activities were observed for the following drug metabolizing enzymes: CYP1A2 (phenacetin hydroxylation), CYP2A6 (coumarin 7-hydroxylation), CYP2B6 (bupropion hydroxylation), and CYP2D6
(dextromethorphan hydroxylation). Ranking of activities in descending order is as follows:
CYP3A4 (testosterone) > SULT> UGT> CYP3A4 (midazolam)>CYP2C9>CYP2J2>CYP2C19=CYP2E1>CES2>CYP2C8
Our ranking of the quantifiable drug metabolizing enzymes in enterocytes are consistent with that reported by others for P450 (Paine et al. 2006; Xie et al. 2016) , UGT (Bock 2016; Radominska-Pandya et al. 1998) , and SULT (Chen et al. 2003; Teubner et al. 2007) , with CYP3A4 and UGT are believed to be the most important drug metabolizing enzymes responsible for metabolism-dependent enteric drug bioavailability. One interesting observation is that lack of significant CYP2D6 activity in the intestines, as this P450 isoform is known to be specifically responsible for hepatic metabolism of a large number of commonly used human drugs, especially for antipsychotic drugs (Vandel et al. 1999 ). The lack of CYP2D6 activities is consistent with the findings with oxycodone metabolism by intestinal mucosal microsomes where the CYP3A4 mediated N-demethylation, but not the CYP2D6-mediated Odemethylation was observed (Lalovic et al. 2004 ). individual differences in bioavailability for orally administered drugs (Jamei et al. 2009 ). Our results suggest that enterocytes from individuals with different drug metabolizing enzyme activities may be used to evaluate this important drug property. However, It is to be added that cryopreservation may lead to attenuation of drug metabolizing enzyme activities. This possibility is being investigated in our laboratory. For now, our data definitively demonstrate that the cryopreserved enterocytes were active in the drug metabolizing enzyme activities evaluated. Whether the cryopreserved enterocyte reflect in vivo activities is yet to be determined.
Besides the metabolic activities shown here, we have quantified gene expression of the enterocytes from the multiple donors and demonstrated that the cells consistently express enterocyte-specific markers, P450 isoforms, uptake and efflux transporters (manuscript in preparation).
Cryopreserved enterocytes may represent the "gold standard" for enteric metabolism studies, as do human hepatocytes for hepatic metabolism (Fabre et al. 1990 ; enteric drug-drug and food-drug interactions which occurs specifically in the intestine but not in the liver, as exemplified by the findings with grapefruit juice on intestinal drug metabolism (Holmberg et al. 2014) , uptake (Shirasaka et al. 2013 ) and efflux (Wang et al. 2001) . A major focus of our laboratory currently is the development of experimental approaches using cryopreserved human enterocytes to evaluate key enteric drug properties including metabolic clearance, metabolite profiling, transportermediated uptake and efflux, P450 inhibition and induction, and enterotoxicity.
Authorship Contributions
Participated in research design: Li, A.P., Ho, D., Doshi, U.
Conducted experiments: Ho, D., Amaral, K., Ring, N., and Doshi, U.
Performed data analysis: Ho, D., Ring, N., Doshi, U., and Li, A.P. 
